U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06889402) titled 'Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy' on March 17.
Brief Summary: Esophageal cancer is one of the most common malignant tumors worldwide, with high invasiveness and lethality. Currently, the treatment for resectable locally advanced esophageal cancer mainly consists of a treatment model centered on surgical treatment with the participation of multiple disciplines. Neoadjuvant treatment regimens include chemotherapy, chemoradiotherapy, and chemotherapy combined with immunotherapy. Complete pathological response (pCR)is currently regarded as one of the important indica...